Key facts
- Anumana’s last known valuation is $580.0M (Mar 2025).
- It has raised $185.3M across 3 recorded rounds; the latest was Early Stage VC ($95.4M) in Mar 2025.
- Notable investors include MedTech Innovator, Matrix, Mayo Clinic, Mayo Clinic Ventures, Matrix Capital Management — 8 tracked in total.
- Anumana has filed 1 Form D with the SEC, most recently Nov 2022 ($32.0M sold to 72 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Anumana
Funding rounds
3 roundsAbout Anumana
Developer of an AI-driven medical technology designed to enhance early diagnosis and intervention in cardiovascular care. The company's platform integrates algorithms with existing clinical workflows, facilitating the transformation of unstructured data into actionable insights, enabling healthcare providers to identify hidden cardiovascular diseases early and improve patient outcomes through timely interventions.
- Industry
- Decision/Risk Analysis
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 163
- Website
- anumana.ai/
- Ownership
- Privately Held (backing)
Anumana doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anumana shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anumana in its N-PORT filings yet. We sweep new filings monthly.